Cancer drug shows promise for rare gene mutation, but study halted early
NCT ID NCT05023655
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called tazemetostat in people with advanced solid tumors that have a specific gene change (ARID1A mutation). The drug works by blocking a protein that helps these tumors grow. The study aimed to see if the drug could shrink tumors or stop them from growing. It was stopped early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARID1A GENE MUTATION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Prisma Health Cancer Institute
Greenville, South Carolina, 29605, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shield nerves from Chemotherapy's side effects?
- Can a Tumor's DNA guide better cancer care for kids?
- Can a new PET tracer reveal a key cancer target?
- Can a smart drug home in on Hard-to-Treat cancers?
- Can a new tracer light up cancer growth?
- Can a Dual-Pronged antibody outsmart advanced cancers?